Fabry disease and lysosomal storage disorders
Research activity is centered on Fabry disease, with attention to alpha-galactosidase A replacement through gene therapy approaches and long-term clinical follow-up in affected subjects.
- Fabry disease
- Alpha-galactosidase A gene therapy
- Long-term safety and tolerability
The sponsor’s clinical work in this area includes ongoing interest in durable treatment effects and extended safety monitoring for inherited metabolic disease.
Kidney transplant rejection and transplant immunology
Clinical research also includes kidney transplant rejection, reflecting involvement in transplant immunology and immune-mediated complications affecting graft survival.
- Kidney transplant rejection
- Graft immune response
- Transplant-related safety
This area indicates therapeutic interest in conditions where immune control and organ preservation are central clinical concerns.
Gene therapy and genetic medicine
The sponsor’s portfolio includes gene therapy programs built around treatment of inherited disease, with emphasis on AAV-based delivery platforms and correction of underlying genetic deficiency.
- Gene therapy
- AAV-based vectors
- Inherited metabolic disease
These activities place genetic intervention at the center of its therapeutic research interests.
Long-term follow-up and treatment durability
Several studies focus on extended observation after treatment, with attention to long-term follow-up, persistent safety, and ongoing tolerability in chronic genetic disease settings.
- Long-term follow-up
- Durability of response
- Chronic safety monitoring
This reflects a clinical interest in sustained therapeutic benefit and continued patient monitoring over time.
